Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.61 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | KCNA3 | P22001 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8191292 | 0.94 | OPRM1 (0.58) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL8186016 | 0.92 | OPRM1 (0.60) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL5307020 | 0.88 | OPRM1 (0.61) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL7603077 | 0.86 | HRH1 (0.46) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL7605289 | 0.84 | HRH1 (0.45) | OPRM1OPRK1SLC22A1SLC6A4ADRA1A | |
| Hydrochloric Acid SCHEMBL8186699 | 0.83 | HRH1 (0.45) | OPRM1OPRD1OPRK1MEN1LMNA | |
| SCHEMBL7609144 | 0.80 | TET3 (0.46) | OPRM1OPRK1SLC6A4ADRA1AKCNH2 | |
| SCHEMBL11712840 | 0.79 | OPRM1 (0.82) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Hydrochloric Acid SCHEMBL8191035 | 0.79 | TET3 (0.45) | OPRM1OPRK1SLC6A4ADRA1AKCNH2 | |
| SCHEMBL11601769 | 0.78 | OPRM1 (0.80) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130204238-A1 | COMBINATION THERAPY | FOLLICA, INC (US) | 2013-08-08 | — | — | US | disclosed |
| US-8252749-B2 | Methods, kits, and compositions for generating new hair follicles and growing hair | FOLLICA, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120156228-A1 | Methods, Kits, and Compositions for Generating New Hair Follicles and Growing Hair | FOLLICA, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110130706-A1 | SEQUENTIAL BODY SURFACE TREATMENT | FOLLICA, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130711-A1 | HAIR GROWTH TREATMENT | FOLLICA, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130748-A1 | BODY SURFACE TREATMENT | FOLLICA, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20100298760-A1 | METHODS, KITS, AND COMPOSITIONS FOR ADMINISTERING PHARMACEUTICAL COMPOUNDS | PURETECH VENTURES | 2010-11-25 | — | — | US | disclosed |
| EP-0738262-B1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK AS (DK) | 2000-04-19 | — | — | EP | disclosed |
| US-6048856-A | ANALGESICS; ANTIINFLAMMATORY AGENTS | NOVO NORDISK A/S (DK) | 2000-04-11 | — | — | US | disclosed |
| US-6043239-A | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS THEREOF IN WHICH A SUBSTITUTED ALKYL CHAIN FORMS PART OF THE N-SUBSTITUENT; TREATMENT OF PAINFUL, HYPERALGESIC AND/OR INFLAMMATORY CONDITIONS | NOVO NORDISK A/S (DK) | 2000-03-28 | — | — | US | disclosed |
| WO-1999031058-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1999-06-24 | — | — | WO | disclosed |
| EP-0820451-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-01-28 | — | — | EP | disclosed |
| US-5668129-A | ANTIINFLAMMATORY AGENTS, ANALGESICS OR ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 1997-09-16 | — | — | US | disclosed |
| US-5595989-A | ANTIINFLAMMATORY AGENTS AND ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 1997-01-21 | — | — | US | disclosed |
| EP-0738262-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1996-10-23 | — | — | EP | disclosed |
| WO-1996031498-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1996-10-10 | — | — | WO | disclosed |
| WO-1995018793-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156228-A1 | Methods, Kits, and Compositions for Generating New Hair Follicles and Growing Hair | NGF, HDGF, SHH | OPRM1 4860/4885OPRD1 4845/4885OPRK1 4835/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | OPRM1 4354/4885OPRD1 4223/4885OPRK1 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.